Lol, no afford, no one's making anything up. Relax my man ;). I personally misunderstood that theirs would not be a LBA, but felt clear they were presenting data that LP and staff were "quite encouraged" by. Everything we need to know about the ASCO meeting and NWBO's place in it is available publicly at the ASCO website. The Direct trial can only possibly qualify for two sessions. I should have looked closer--it would have kept me from mixing up the abstract designation. Here is a summary:
-NWBO submitted an abstract for the DCVax Direct trial with data collected up to as late as February. It is, by definition, not a LBA, nor a TIP abstract.
-Their abstract title only will be available next week (Apr 21). Just the title. That might give us some clues as to what will be in the abstract and thus meeting (ASCO).
-The full abstract will go public May 14th. This will give us some clues as to what's in the full study report (undisclosed until ASCO). It will in format be similar to most study abstracts.
-The full study data, including any results tabulated up until May 19th, will be fully disclosed during one of two sessions at ASCO itself, on May 30th. I am of the opinion it will be during the oral sessions. Vivek Subbiah will conduct the talk. Incidentally, this is the same day the LBAs become disclosed, and will continue to over the following days (not relevant to NWBO).
-At the same time or immediately following that session in which data accumulated in the Direct trial up until 5/19 is divulged, a public release will occur in which we are all notified of the same. And I am expecting those results to show significant effect, especially in regards to tumor necrosis, and possibly evidence of systemic response (less likely at this early stage, imo).
News 
Market Data 
Discover 
